Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate - Bone Marrow Transplantation
- ️Litzow, M R
- ️Mon Nov 01 2004
Perfetti V, Vignarelli MC, Casarini S et al. Biological features of the clone involved in primary amyloidosis (AL). Leukemia 2001; 15: 195–202.
Kyle RA . Clinical aspects of multiple myeloma and related disorders including amyloidosis. Pathol Biol (Paris) 1999; 47: 148–157.
Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–3670.
Dispenzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350–3356.
Comenzo RL, Gertz MA . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282.
Comenzo RL, Sanchorawala V, Fisher C et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104: 553–559.
Elghetany MT, Saleem A . Methods for staining amyloid in tissues: a review. Stain Technol 1988; 63: 201–212.
Kaplan B, Vidal R, Kumar A et al. Immunochemical microanalysis of amyloid proteins in fine-needle aspirates of abdominal fat. Am J Clin Pathol 1999; 112: 403–407.
Moreau P, Facon T, Attal M et al, for the Intergroupe Francophone du Myelome. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.
Bladé J, Samson D, Reece D et al, for the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant) Chronic Leukaemia Working Party and the Myeloma Working Committee of the IBMTR (International Bone Marrow Transplant Registry) and ABMTR (Autologous Blood and Marrow Transplant Registry). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.
Bradwell AR, Carr-Smith HD, Mead GP et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489–491.
Abraham RS, Katzmann JA, Clark RJ et al. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274–278.
Henon P, Sovalat H, Bourderont D et al. Role of the CD34+ 38− cells in posttransplant hematopoietic recovery. Stem Cells 1998; 16 (Suppl. 1): 113–122.
Murray S . Using weighted Kaplan–Meier statistics in nonparametric comparisons of paired censored survival outcomes. Biometrics 2001; 57: 361–368.
Gertz MA, Kyle RA, Greipp PR . Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257–262.
Jones NF, Hilton PJ, Tighe JR, Hobbs JR . Treatment of ‘primary’ renal amyloidosis with melphalan. Lancet 1972; 2: 616–619.
Child JA, Morgan GJ, Davies FE et al, for the Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.
Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642.
Dember LM, Sanchorawala V, Seldin DC et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746–753.
Saba N, Sutton D, Ross H et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853–855.
Gertz MA, Lacy MQ, Dispenzieri A et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113: 549–555.
Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766–769.
Sanchorawala V, Wright DG, Seldin DC et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002; 117: 886–889.
McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.
Selby PJ, McElwain TJ, Nandi AC et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55–62.
Gertz MA, Kyle RA, Greipp PR et al. Beta 2-microglobulin predicts survival in primary systemic amyloidosis. Am J Med 1990; 89: 609–614.
Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.
Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.
Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.
San Miguel JF, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1: 28–36.
Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.
Skinner M, Sanchorawala V, Seldin DC et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93.
Lachmann HJ, Gallimore R, Gillmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78–84.
Palladini G, Perfetti V, Obici L et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938.